BGI Genomics Co (300676.SZ) Stock Price

BGI Genomics Co Price

SZSE·CLOSED
32.78
​
Market closed

Over the last 13 years BGI Genomics Co grew revenue by 12.6% annually, reaching 3.71 B CNY. Earnings per share have grown at 1.2% per year over the last 11 years. For BGI Genomics Co, the net margin of -16.6% is down versus 21.6% a few years ago. At today's price the dividend yield works out to roughly 0.31%. The consensus 12-month price target for BGI Genomics Co is 58.87 CNY, about 79.6% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.

BGI Genomics Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BGI Genomics Co business model & stock analysis

BGI Genomics Co., Ltd. generates revenue through its core services in genomics, including reproductive health basic research and clinical application services, basic science research services such as genome sequencing and bioinformatics analysis, complex disease research and clinical applications, and drug-related research services. The company primarily serves academic institutions, research institutes, independent laboratories, pharmaceutical companies, hospitals, and medical institutions both domestically and internationally. Its domestic market focus allows it to cater to a wide range of clients seeking advanced genomic solutions for research and healthcare applications. The firm's revenue streams are derived from providing specialized genomic services to institutions and companies involved in medical research and healthcare. By offering multithreaded solutions in genome sequencing and bioinformatics, BGI Genomics supports clients in advancing their scientific and clinical objectives. The company's domestic market operations enable it to maintain strong relationships with key stakeholders in China's healthcare and research sectors. BGI Genomics' service portfolio includes reproductive health, complex disease, and drug development research, all of which are critical areas for pharmaceutical and medical institutions. These services are tailored to meet the needs of academic and commercial clients, driving demand for its genomic analysis and research support. The company's focus on domestic operations ensures alignment with local healthcare and research priorities.

Frequently asked questions about BGI Genomics Co

Analysts currently set an average price target of 58.87 CNY for the BGI Genomics Co stock (median: 58.87 CNY), implying +79.6 % versus the latest price. The consensus is based on 5 analyst ratings.

5 analysts currently rate the BGI Genomics Co stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect BGI Genomics Co to generate revenue of 3.96 B CNY and earnings per share of 0.27 CNY.

Converted at the current exchange rate, the BGI Genomics Co share trades at 4.47 EUR (32.78 CNY).

The BGI Genomics Co share (300676.SZ) is listed on 1 stock exchanges, including: Shenzhen (300676.SZ).

The expected revenue of BGI Genomics Co is 3.96 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of BGI Genomics Co is 111.34 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of BGI Genomics Co is currently 122.56. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BGI Genomics Co stock.

The price-to-sales ratio (P/S) of BGI Genomics Co is currently 3.44. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BGI Genomics Co stock.

The Eulerpool Quality Score for BGI Genomics Co is 1/10.

The ISIN of BGI Genomics Co is CNE100003449. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of BGI Genomics Co is 300676.SZ. The ticker symbol is used to trade BGI Genomics Co shares on the stock exchange.

Fair ValueTerminal
33.76 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
833,045.19 CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website bgi.com
Country
Currency
CNY
Initial public offering
Jul 14, 2017
ISIN
CNE100003449
Cusip
Y0883H107
Market capitalization
13.52 B CNYLarge Cap
52-Week Range
PEG
-1.32
P/E ratio
P/Ee 2026
121.41
P/Ee 2027
96.41
P/Ee 2028
76.23
P/S
P/Se
3.44
EV/EBIT
—
P/B Ratio
1.59
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-6.90 %
Dividend
Dividend yield
0.00 %
Est. Dividend Yield
0.31 %
Payout Ratio
158.09 %
Dividend growth Ø5Y
-27.52 %
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
10.00 %
Last updated Nov 22, 2026, 3:38 AM

BGI Genomics Co Peer Group

BGI Genomics Co Ticker

SHZ · 300676.SZ

BGI Genomics Co FIGI

300676:CH · BBG00BQVVS66300676:CS · BBG00BQVVS84300676:C2 · BBG00LBJFCZ8